Literature DB >> 12663762

Progesterone increases susceptibility and decreases immune responses to genital herpes infection.

Charu Kaushic1, Ali A Ashkar, Lesley A Reid, Kenneth L Rosenthal.   

Abstract

Depo-provera, a long-acting progestational formulation, is widely used to facilitate infection of sexually transmitted diseases in animal models. We have previously reported that hormone treatments change susceptibility and immune responses to genital tract infections. In this study we compared the changes in susceptibility of mice to genital herpes simplex virus type 2 (HSV-2) after Depo-provera or a saline suspension of progesterone (P-sal). We found that following Depo-provera-treatment, mice had prolonged diestrus that lasted more than 4 weeks. This coincided with a 100-fold increase in susceptibility to genital HSV-2 compared to that of untreated mice. Mice given P-sal were in diestrous stage for 4 to 6 days before returning to irregular reproductive cycles. When these mice were infected at diestrus they showed a 10-fold increase in susceptibility compared to that of normal, untreated mice. P-sal-treated mice infected at estrus were susceptible to HSV-2, depending on the infectious dose. Normal, untreated mice in estrus were not susceptible to HSV-2, even at a high infectious dose of 10(7) PFU. In addition to alterations in susceptibility, Depo-provera treatment had inhibitory effects on immune responses to HSV-2. Mice immunized with HSV-2 protein (gB) and treated with Depo-provera showed significant lowering of local HSV-2-specific immunoglobulin G (IgG) and IgA in their vaginal washes. Mice immunized with an attenuated strain of HSV-2 2 weeks after Depo-provera treatment failed to develop protection when challenged intravaginally with wild-type HSV-2. In contrast, mice given progesterone and immunized at diestrus or estrus were completely protected from intravaginal challenge. These studies show that Depo-provera treatment changes susceptibility and local immune responses to genital HSV-2 infection. Animal models and vaccine strategies for sexually transmitted diseases need to consider the effect of hormone treatments on susceptibility and immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663762      PMCID: PMC152159          DOI: 10.1128/jvi.77.8.4558-4565.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Role of mucosal immunity in herpes simplex virus infection.

Authors:  N A Kuklin; M Daheshia; S Chun; B T Rouse
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

2.  Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract.

Authors:  C Kaushic; F Zhou; A D Murdin; C R Wira
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.

Authors:  W S Gallichan; R N Woolstencroft; T Guarasci; M J McCluskie; H L Davis; K L Rosenthal
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

4.  Sex steroid hormone regulation of IgA and IgG in rat uterine secretions.

Authors:  C R Wira; C P Sandoe
Journal:  Nature       Date:  1977-08-11       Impact factor: 49.962

Review 5.  IgA and mucosal defense.

Authors:  M E Lamm; J G Nedrud; C S Kaetzel; M B Mazanec
Journal:  APMIS       Date:  1995-04       Impact factor: 3.205

6.  Regulation of polymeric immunoglobulin A receptor messenger ribonucleic acid expression in rodent uteri: effect of sex hormones.

Authors:  C Kaushic; J M Richardson; C R Wira
Journal:  Endocrinology       Date:  1995-07       Impact factor: 4.736

7.  Antigen-presenting cells in the female reproductive tract: influence of the estrous cycle on antigen presentation by uterine epithelial and stromal cells.

Authors:  C R Wira; R M Rossoll
Journal:  Endocrinology       Date:  1995-10       Impact factor: 4.736

8.  Effect of the estrous cycle on susceptibility of female mice to intravaginal inoculation of herpes simplex virus type 2 (HSV-2).

Authors:  A G Teepe; L B Allen; R J Wordinger; E F Harris
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

9.  Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2.

Authors:  M R McDermott; J R Smiley; P Leslie; J Brais; H E Rudzroga; J Bienenstock
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

10.  A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.

Authors:  M B Parr; L Kepple; M R McDermott; M D Drew; J J Bozzola; E L Parr
Journal:  Lab Invest       Date:  1994-03       Impact factor: 5.662

View more
  114 in total

1.  Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1.

Authors:  Felix N Toka; Malgorzata Gierynska; Barry T Rouse
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 2.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

3.  T cell response kinetics determines neuroinfection outcomes during murine HSV infection.

Authors:  Aisha G Lee; Jason M Scott; Maria Rita Fabbrizi; Xiaoping Jiang; Dorothy K Sojka; Mark J Miller; Megan T Baldridge; Wayne M Yokoyama; Haina Shin
Journal:  JCI Insight       Date:  2020-03-12

4.  The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.

Authors:  Léanie Kleynhans; Nelita Du Plessis; Nasiema Allie; Muazzam Jacobs; Martin Kidd; Paul D van Helden; Gerhard Walzl; Katharina Ronacher
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

5.  Pregnancy Alters Innate and Adaptive Immune Responses to Zika Virus Infection in the Reproductive Tract.

Authors:  Kelsey E Lesteberg; Dana S Fader; J David Beckham
Journal:  J Immunol       Date:  2020-10-30       Impact factor: 5.422

6.  Optical coherence tomography for assessment of microbicide safety in a small animal model.

Authors:  Brent A Bell; Kathleen L Vincent; Nigel Bourne; Gracie Vargas; Massoud Motamedi
Journal:  J Biomed Opt       Date:  2013-04       Impact factor: 3.170

7.  Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.

Authors:  Alison J Johnson; Chin-Fun Chu; Gregg N Milligan
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

Review 9.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

10.  An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus.

Authors:  Christopher D Pack; Malgorzata Gierynska; Barry T Rouse
Journal:  Hum Vaccin       Date:  2008-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.